Clinical and Experimental Nephrology

, Volume 17, Issue 2, pp 304–309

Use of the ImmuKnow assay to evaluate the effect of alemtuzumab-depleting induction therapy on cell-mediated immune function after renal transplantation

  • Hao Zhou
  • Jian Lin
  • Shushang Chen
  • Liqiang Ma
  • Zhenzhen Qiu
  • Weidong Chen
  • Xin’an Zhang
  • Yi Zhang
  • Xiuquan Lin
Original Article

DOI: 10.1007/s10157-012-0688-1

Cite this article as:
Zhou, H., Lin, J., Chen, S. et al. Clin Exp Nephrol (2013) 17: 304. doi:10.1007/s10157-012-0688-1

Abstract

Background

Good outcomes after renal transplantation are dependent on effective immunosuppression while minimizing infection. Alemtuzumab (Campath or Campath-1H) is an anti-CD52 humanized monoclonal IgG1 antibody which induces rapid and sustained depletion of circulating lymphocytes and has been effectively used as an immunosuppressant in post-transplant induction therapy.

Methods

We used the ImmuKnow assay to compare cell-mediated immune function in renal transplant patients treated with alemtuzumab or with conventional immunosuppressive tri-therapy. The ImmuKnow method determines the levels of adenosine triphosphate (ATP) released from CD4 cells following stimulation with a mitogen.

Results

We showed a statistically significant difference in the distribution of outcome after transplantation between the conventional and the Campath groups (P = 0.010). A significantly higher number of patients treated with alemtuzumab induction therapy were stable after transplantation compared to those treated with conventional immunosuppressive tri-therapy (96.6 vs. 75.7 %). ATP values were significantly higher in the conventional group compared to the Campath group at 180 days after transplantation (P < 0.001). ATP levels did not change significantly over time in clinically stable kidney recipients treated with alemtuzumab induction therapy (P = 0.554).

Conclusions

The ImmuKnow assay is a useful tool for evaluating the global immune response in alemtuzumab-treated renal transplant patients. Alemtuzumab-depleting induction therapy remains effective for at least 180 days.

Keywords

Alemtuzumab Cell-mediated immunity ImmuKnow Immunosuppression Renal transplant 

Copyright information

© Japanese Society of Nephrology 2012

Authors and Affiliations

  • Hao Zhou
    • 1
    • 2
    • 3
  • Jian Lin
    • 4
  • Shushang Chen
    • 2
    • 3
  • Liqiang Ma
    • 5
    • 6
  • Zhenzhen Qiu
    • 7
  • Weidong Chen
    • 1
  • Xin’an Zhang
    • 1
  • Yi Zhang
    • 1
  • Xiuquan Lin
    • 8
  1. 1.Department of UrologyPeople’s Hospital Affiliated to Fujian University of Traditional Chinese Medicine (The People’s Hospital of Fujian Province)FuzhouChina
  2. 2.Department of UrologyFuzhou General Hospital, Fujian Medical University, Second Military Medical UniversityFuzhouChina
  3. 3.Department of UrologyDongfang Hospital, Xiamen UniversityFuzhouChina
  4. 4.First Hospital of Nanping CityFujian Medical University, Fujian University of Traditional Chinese MedicineNanpingChina
  5. 5.Department of LaboratoryFuzhou General Hospital, Fujian Medical University, Second Military Medical UniversityFuzhouChina
  6. 6.Department of LaboratoryDongfang Hospital, Xiamen UniversityFuzhouChina
  7. 7.Minjiang UniversityFuzhouChina
  8. 8.Department of Chronic Disease PreventionFujian Center for Disease Control and PreventionFuzhouChina